Abstracts Archive - Page 815 of 2425 - ACR Meeting Abstracts

Abstract Number: 849 • 2019 ACR/ARP Annual Meeting
Risk of Malignancies Associated with Biologics in Rheumatoid Arthritis: Analysis of a National Claim Database
Raphaèle Seror¹, Alexandre Lafourcade ², yann De Rycke ², Bruno Fautrel ³, Xavier Mariette ⁴ and Florence Tubach ⁵, ¹Université Paris Sud, Hôpitaux Universitaires Paris-Sud, AP-HP, INSERM UMR 1184, Le Kremlin-Bicêtre, France, ²Biostatistics, Public Health and Medical Information department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France, Paris, France, ³Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, ⁴Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, ⁵Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France
Background/Purpose: Our objectives were to estimate and compare the incidence rate of malignancies between biologic and csDMARD-treated RA patients.Methods: We conducted an historical cohort study…
Abstract Number: 850 • 2019 ACR/ARP Annual Meeting
Safety of Synthetic and Biological DMARDs: A Systematic Literature Review Informing the 2019 Update of the EULAR Recommendations for Management of Rheumatoid Arthritis
Alexandre Sepriano¹, Andreas Kerschbaumer ², Josef Smolen ², Désirée van der Heijde ¹, Maxime Dougados ³, Ronald F Van Vollenhoven ⁴, Iain McInnes ⁵, Johannes Bijlsma ⁶, Gerd Burmester ⁷, Maarten de Wit ⁸, Louise Falzon ⁹ and Robert B.M. Landewé ¹⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²Medical University of Vienna, Vienna, Austria, ³Cochin Hospital, Paris, France, ⁴Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ⁵College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁶UMC Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands, Utrecht, Netherlands, ⁷Charité—University Medicine Berlin, Berlin, Germany, ⁸Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam University Medical Centre, Amsterdam, Netherlands, ⁹Northwell Health, New York, ¹⁰Amsterdam University Medical Center, Amsterdam, Netherlands
Background/Purpose: To assess the most recent safety-data of synthetic (s) and biological (b)DMARDs to inform the 2019 update of the EULAR recommendations for the management…
Abstract Number: 851 • 2019 ACR/ARP Annual Meeting
Association Between Bone Marrow Edema and Structural Progression in the Same Quadrant in Axial Spondyloarthritis – 5-year Data from the DESIR Cohort
Santiago Rodrigues-Manica¹, Alexandre Sepriano ², Sofia Ramiro ³, Robert B.M. Landewé ⁴, Pascal Claudepierre ⁵, Anna Molto ⁶, Maxime Dougados ⁷, Miranda van Lunteren ² and Désirée van der Heijde ², ¹CEDOC, NOVA-Medical School | Hospital Egas Moniz, CHLO, Lisbon, Lisbon, Portugal, ²Leiden University Medical Center, Leiden, Netherlands, ³Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands, ⁴Amsterdam University Medical Center, Amsterdam, Netherlands, ⁵Rheumatology, CHU Henri Mondor Créteil, Paris, France, ⁶Paris Descartes University, Medicine Faculty; APHP, Rheumatology, Hôpital Cochin, Hôpitaux de Paris, Paris, Paris, France, ⁷Cochin Hospital, Paris, France
Background/Purpose: The overall presence of inflammation in the MRI-SIJ is associated with overall 5-year radiographic damage in patients with axSpA. But we do not know…
Abstract Number: 852 • 2019 ACR/ARP Annual Meeting
Ileal but Not Colonic Inflammation Is Linked to Fatty Lesions on MRI of the Sacroiliac Joints in Spondyloarthritis Patients
Ann-Sophie De Craemer¹, Manouk de Hooge ¹, Thomas Renson ¹, Liselotte Deroo ¹, Triana Lobaton Ortega ², Anne Hoorens ³, Philippe Carron ¹, Filip Van den Bosch ¹ and Dirk Elewaut ¹, ¹Ghent University Hospital, Ghent, Belgium, ²Ghent University Hospital, Gent, Oost-Vlaanderen, Belgium, ³Ghent University Hospital, Gent
Background/Purpose: Gut and joint inflammation in spondyloarthritis (SpA) are closely intertwined. About 50% of axial SpA patients display microscopic signs of inflammation in ileum and/or…
Abstract Number: 853 • 2019 ACR/ARP Annual Meeting
Two-Year Progression of Facet Joint Ankylosis on Whole Spine Low-Dose CT in Patients with Radiographic Axial Spondyloarthritis
Rosalinde Stal¹, Floris van Gaalen ¹, Alexandre Sepriano ¹, Jürgen Braun ², Monique Reijnierse ¹, Désirée van der Heijde ¹ and Xenofon Baraliakos ³, ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany, ³Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany
Background/Purpose: Inflammation and new bone formation in the axial skeleton are characteristic features of radiographic axial spondyloarthritis (r-axSpA). Facet joints are frequently involved in r-axSpA…
Abstract Number: 854 • 2019 ACR/ARP Annual Meeting
Do Smoking and Socio-economic Factors Independently Influence Imaging Outcomes in Axial Spondyloarthritis? Five-year Data from the DESIR Cohort
Elena Nikiphorou¹, Sofia Ramiro ², Alexandre Sepriano ³, Adeline Ruyssen Witrand ⁴, Robert B.M. Landewé ⁵ and Désirée van der Heijde ³, ¹King's College London, London, United Kingdom, ²Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology center, Pierre Paul Riquet Hospital, CHU of Toulouse, Paul Sabatier University, UMR 1027, Inserm, France, Toulouse, France, ⁵Amsterdam University Medical Center, Amsterdam, Netherlands
Background/Purpose: Smoking and systemic inflammation have been shown to independently associate with radiographic spinal progression in patients with axSpA. Evidence suggests that certain socioeconomic (SE)…
Abstract Number: 855 • 2019 ACR/ARP Annual Meeting
Which Magnetic Resonance Imaging Lesions of the Sacroiliac Joints Are of Diagnostic Value for Axial Spondyloarthritis?
Xenofon Baraliakos¹, Anna Ghadir ², Martin Fruth ², Uta Kiltz ³ and Jürgen Braun ⁴, ¹Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ²Radiology Herne, Herne, Germany, ³Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany
Background/Purpose: Classification of patients as having axial spondyloarthritis (axSpA) by the imaging arm of the ASAS criteria relies partly on the detection of bone marrow…
Abstract Number: 856 • 2019 ACR/ARP Annual Meeting
MRI of the Sacroiliac Joints in Athletes: Do Semi-axial Slices Added to Standard Semi-coronal Scans Facilitate Recognition of Non-specific Bone Marrow Edema?
Ulrich Weber¹, Anne Grethe Jurik ², Anna Zejden ², Ejnar Larsen ³, Steen Hylgaard Jørgensen ⁴, Kaspar Rufibach ⁵, Christian Schioldan ⁶ and Søren Schmidt-Olsen ⁷, ¹Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sonderborg, Denmark, ²Department of Radiology, Aarhus University Hospital, Aarhus, Denmark, ³Department of Radiology, North Denmark Regional Hospital, Hjørring, Denmark, ⁴Center for Clinical Research, North Denmark Regional Hospital, Hjørring, Denmark, ⁵Division of Biostatistics, F. Hoffmann-La Roche, Basel, Switzerland, ⁶Department of Physiotherapy, Clinic Benefit, Frederikshavn, Denmark, ⁷Department of Rheumatology and Sports Medicine, North Denmark Regional Hospital, Hjørring, Denmark
Background/Purpose: Low grade bone marrow edema (BME) on magnetic resonance imaging (MRI) of the sacroiliac joints (SIJ) is challenging the discrimination between patients with early…
Abstract Number: 857 • 2019 ACR/ARP Annual Meeting
Mesenchymal Stem Cell Therapy Induces FLT3L and CD1c+ Dendritic Cells in Systemic Lupus Erythematosus Patients
Xinran Yuan ¹, Dandan Wang ¹ and Lingyun Sun², ¹Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China (People's Republic), ²The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China (People's Republic)
Background/Purpose: Allogeneic mesenchymal stem cells (MSCs) exhibit immunoregulatory function in human autoimmune diseases such as systemic lupus erythematosus (SLE), but the underlying mechanisms remain incompletely…
Abstract Number: 858 • 2019 ACR/ARP Annual Meeting
Adverse Events of Special Interest, SLE Medication Utilization, Hospitalizations, and Organ Damage: Results from a Phase 4, Randomized, Double-Blind, Placebo-Controlled, 52-week Study of Belimumab in Adults with Active, Autoantibody-Positive SLE
Saira Sheikh¹, Morton Scheinberg ², Cheng-Chung Wei ³, Dana Tegzova ⁴, William Stohl ⁵, Ricardo Acayaba de Toledo ⁶, Tamara Mucenic ⁷, Mauricio Abello Banfi ⁸, Kathleen Maksimowicz-McKinnon ⁹, Carlos Abud-Mendoza ¹⁰, Sandra Navarra ¹¹, Mercedes Garcia ¹², Ignacio Garcia-De La Torre ¹³, Josep Ordi Ros ¹⁴, Roger Abramino Levy ¹⁵, Damon L Bass ¹⁵, Jorge Ross Terrés ¹⁶, Raj Punwaney ¹⁶, Julia Harris ¹⁷, Alireza Nami ¹⁸, Amy Pierce ¹⁹, Kevin Thorneloe ²⁰, Beulah Ji ¹⁷ and David Roth ¹⁶, ¹University of North Carolina, Chapel Hill, NC, ²Centro de Pesquisas Clinicas do Hospital Abreu Sodré, São Paulo, Brazil, ³Chung Shan Medical University, Taichung City, Taiwan (Republic of China), ⁴Institute of Rheumatology, Prague, Czech Republic, ⁵University of Southern California Keck School of Medicine, Los Angeles, CA, ⁶Faculdade de Medicina de São José do Rio Preto, São Paulo, Brazil, ⁷Hospital Moinhos Angeles de Vento, Porto Alegre, Brazil, ⁸Centro Integral de Reumatología del Caribe, Barranquilla, Colombia, ⁹Henry Ford Hospital, Wayne State University, Detroit, MI, ¹⁰Hospital Central “Dr Ignacio Morones Prieto”, Unidad Regional de Reumatologia y Osteoporosis, Hospital Central and Facultad de Medicina de la Universidad Autónoma de San Luis Potosí, San Luis Potosi, Mexico, ¹¹University of Santo Tomas Hospital, Manila, Philippines, ¹²Hospital San Martín, La Plata, Argentina, ¹³Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Jalisco, Mexico, ¹⁴Hospital Vall d'Hebron, Barcelona, Spain, ¹⁵GlaxoSmithKline, Collegeville, PA, ¹⁶GSK, Collegeville, PA, ¹⁷GSK, Uxbridge, Middlesex, United Kingdom, ¹⁸Joint Muscle Medical Care and Research Institute, Charlotte, NC, ¹⁹ViiV Healthcare, Research Triangle Park, NC, ²⁰GSK, Collegeville, NC
Background/Purpose: Belimumab (BEL), approved in active, autoantibody-positive SLE, has demonstrated a positive efficacy/safety profile while suggesting potential for steroid sparing and reduced organ damage accrual.…
Abstract Number: 859 • 2019 ACR/ARP Annual Meeting
Long-term Outcome of a Randomized Controlled Trial Comparing Tacrolimus with Mycophenolate Mofetil as Induction Therapy of Severe Lupus Nephritis
Chi Chiu Mok¹, Ling Yin Ho ², Shirley Ying ³, Woon Leung Ng ⁴ and Man Chi Leung ⁴, ¹Department of Medicine, Tuen Mun Hospital, Hong Kong, China (People's Republic), ²Tuen Mun Hospital, Hong Kong, Hong Kong, ³Princess Margaret Hospital, Hong Kong, Hong Kong, ⁴United Christian Hospital, Hong Kong, Hong Kong
Background/Purpose: To report the 10-year outcome of patients with lupus nephritis (LN) treated with combined prednisolone with mycophenolate mofetil (MMF) or tacrolimus (TAC) as induction…
Abstract Number: 860 • 2019 ACR/ARP Annual Meeting
Efficacy of Belimumab in Patients of Black Race with Systemic Lupus Erythematosus and High Disease Activity or Renal Manifestations
Luiz Sergio Guedes Barbosa ¹, Amit Saxena ², Ellen M Ginzler ³, Richard Furie⁴, David D'Cruz ⁵, Susan Burriss ⁶, Jennifer Gilbride ⁷, Michelle Miller ⁶, James Groark ⁶, David Roth ⁶ and Beulah Ji ⁸, ¹NUTEC - Núcleo de Terapia Especializada em Cancerologia, Cuiaba, Brazil, ²New York University School of Medicine, New York, NY, ³State University of New York Downstate Medical Center, Brooklyn, NY, ⁴Northwell Health, Great Neck, NY, ⁵The Louise Coote Lupus Unit, Guy's Hospital, London, England, United Kingdom, ⁶GSK, Collegeville, PA, ⁷GSK, Stevenage, Hertfordshire, United Kingdom, ⁸GSK, Uxbridge, Middlesex, United Kingdom
Background/Purpose: Black patients have more severe SLE and more frequent lupus nephritis vs other racial groups. Efficacy and safety of intravenous (IV) belimumab was demonstrated…
Abstract Number: 861 • 2019 ACR/ARP Annual Meeting
Cutaneous Lupus Erythematosus Disease Area & Severity Index (CLASI) Demonstrates Thresholds for Detection of Treatment Response in a Phase-2, Placebo-Controlled Trial of Ustekinumab in SLE
Victoria Werth¹, Bevra Hahn ², George Tsokos ³, Shawn Rose ⁴, Kaiyin Fei ⁴, Yun Gregan ⁴, Robert Gordon ⁴, Kim Hung Lo ⁴ and Ronald van Vollenhoven ⁵, ¹Hospital of the Univ of PA and Veteran’s Administration Med Center, Philadelphia, PA, ²University of California, Los Angeles, CA, ³Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands
Background/Purpose: Ustekinumab (UST), an anti-IL-12/23 p40 monoclonal antibody, showed significantly greater improvement at week (wk) 24 compared with placebo (PBO) in Systemic Lupus Erythematosus Disease…
Abstract Number: 862 • 2019 ACR/ARP Annual Meeting
First Use of Cenerimod, a Selective sphingosine-1-phosphate 1 (S1P1) Receptor Modulator, for the Treatment of Systemic Lupus Erythematosus: A Double-Blind, Randomised, Placebo-Controlled, Phase II, Proof-of-Concept Study
Viktoria Hermann¹, Anastas Batalov ², Svetlana Smakotina ³ and Peter Cornelisse ¹, ¹Idorsia, Allschwil, Switzerland, ²Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, ³Kemerovo Regional Clinical Hospital, Kemerovo, Russia
Background/Purpose: Aberrantly activated T- and B-lymphocytes play a major pathophysiological role in SLE. Cenerimod, a potent, selective sphingosine-1-phosphate 1 receptor modulator, blocks the egress of…
Abstract Number: 863 • 2019 ACR/ARP Annual Meeting
Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis— Results of Phase I/II Investigator-Initiated, Double-Blind Randomized Placebo-Controlled Trial
Dinesh Khanna¹, Erica Bush ², Vivek Nagaraja ², Andrew Koenig ³, Puja Khanna ⁴, Amber Young ⁵, Jeffrey Moore ⁶, David Fox ⁶ and Robert Lafyatis ⁷, ¹Scleroderma Program, Division of Rheumatology, Department of Internal Medicine, Autoimmunity Center of Excellence, University of Michigan, Ann Arbor, ²University of Michigan, Ann Arbor, MI, ³Rheumatology, Collegeville, ⁴University of Michigan Medical School, Ann Arbor, ⁵University of Michigan, Ann Arbot, ⁶University of Michigan, Ann Arbor, ⁷University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Tofacitinib (TOFA) is a potent pan inhibitor of the Janus Kinase (JAK) family of kinases with a high degree of selectivity against JAK1 and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].